Trials / Completed
CompletedNCT01193959
Pemetrexed in Advanced Non-small Cell Lung Cancer
Retrospective Study of Molecular Predictors of Sensitivity and Resistance to Pemetrexed in Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 33 (actual)
- Sponsor
- Armando Santoro, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Present study is aimed at investigating potential molecular predictors of sensitivity or resistance to single-agent pemetrexed in the ≥ second line setting in a large cohort of advanced non-small cell lung cancer (NSCLC) patients. The following biomarkers will be investigated with either immunohistochemistry, fluorescence in situ hybridization or genotyping: thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyl transferase (GARFT), aminoimidazole carboxamide ribonucleotide formyltransferase (ATIC/AICARFT), epidermal growth factor receptor (EGFR), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS), v-myc myelocytomatosis viral oncogene homolog (MYC) and phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA).
Conditions
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2011-12-01
- Completion
- 2012-06-01
- First posted
- 2010-09-02
- Last updated
- 2022-09-10
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01193959. Inclusion in this directory is not an endorsement.